Xcel Pharmaceuticals
Xcel Pharmaceuticals currently focus on neurology, a segment of the CNS market where a limited number of high-prescribing physicians.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD142—213m (Dealroom.co estimates Apr 2003.)
San Diego California (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
$70.0m | Growth Equity VC | ||
$22.0m | Series B | ||
$26.0m | Series C | ||
N/A | Acquisition | ||
Total Funding | CAD161m |
Related Content
Recent News about Xcel Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.